Ebrahimpour Yazdan, Khatami Sahbasadat, Saffar Mahsa, Fereidouni Alireza, Biniaz Zahra, Erfanian Nafiseh, Fereidouni Mohammad
Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran.
Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.
J Diabetes. 2025 Aug;17(8):e70120. doi: 10.1111/1753-0407.70120.
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disorder where the immune system targets and destroys insulin-producing β-cells in the pancreas. It generally emerges during childhood or adolescence, but individuals of any age can be affected. In contrast to Type 2 diabetes mellitus (T2DM) which is often associated with lifestyle factors, T1DM cannot be prevented and necessitates lifelong management. Currently, there is no definitive cure for T1DM, and patients rely on continuous insulin injections for their entire lives. Ongoing developments in insulin treatment, such as insulin pumps, continuous glucose monitoring, and hybrid closed-loop systems, offer promising alternatives. Despite advancements in intensive glycemic control that have reduced the occurrence of microvascular and macrovascular complications, a significant number of T1DM patients still these issues. Extensive research efforts are crucial to achieve early detection, prevent the loss of β-cells, and devise improved treatment strategies to enhance the quality of life and prognosis for those affected. This review explores the most noteworthy and recent advancements in the field of T1DM.
1型糖尿病(T1DM)是一种慢性自身免疫性疾病,免疫系统会攻击并破坏胰腺中产生胰岛素的β细胞。它通常在儿童期或青春期出现,但任何年龄段的人都可能受到影响。与通常与生活方式因素相关的2型糖尿病(T2DM)不同,T1DM无法预防,需要终身管理。目前,T1DM尚无确切的治愈方法,患者一生都依赖持续注射胰岛素。胰岛素治疗方面的不断发展,如胰岛素泵、持续血糖监测和混合闭环系统,提供了有前景的替代方案。尽管强化血糖控制取得了进展,减少了微血管和大血管并发症的发生,但仍有相当数量的T1DM患者存在这些问题。广泛的研究工作对于实现早期检测、防止β细胞丧失以及制定改善治疗策略以提高患者生活质量和预后至关重要。本综述探讨了T1DM领域最值得关注的最新进展。